Open AccessIncremental value of 68-gallium-prostate-specific membrane antigen positron emission tomography/computed tomography in patients with abnormal prostate-specific antigen and benign transrectal ultrasound biopsy
Author(s) -
Manoj Gupta,
Partha Sarathi Choudhury,
Sudhir Rawal,
Gurudutt Gupta
Publication year - 2018
Publication title -
urology annals
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.355
H-Index - 20
eISSN - 0974-7834
pISSN - 0974-7796
DOI - 10.4103/ua.ua_55_17
Subject(s) - medicine , prostate cancer , prostate , biopsy , positron emission tomography , glutamate carboxypeptidase ii , standardized uptake value , radiology , prostate specific antigen , ultrasound , lymph node , urology , nuclear medicine , cancer , pathology
Bladder outlet obstruction due to prostate enlargement is a common health problem in male and frequently investigated with prostate-specific antigen (PSA) and transrectal ultrasound (TRUS). TRUS-guided biopsy is critical to differentiate benign prostatic hyperplasia (BPH) or prostate cancer (PCa) even though it has been associated with false negative with reported 3%-16% incidence of PCa in BPH specimens. Prostate-specific membrane antigen positron emission tomography/computed tomography (PSMA PET/CT), a targeted molecular imaging for PCa, has showed promising results in recurrence and staging. We analyzed its role in patients with abnormal PSA and benign TRUS biopsy.